Hi there!
We track 70,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
Ten63 Therapeutics
Ten63 Therapeutics designs novel, durable therapeutics for hard-to-drug cancer targets by combining physics-based chemistry with AI-driven design. The company is a venture-backed drug discovery…
Ten63 Therapeutics
Ten63 Therapeutics designs novel, durable therapeutics for hard-to-drug cancer targets by combining physics-based chemistry with AI-driven design. The company is a venture-backed drug discovery…
TL;DR
Headquarters: Durham, North Carolina
Focus: AI- and physics-driven drug discovery for hard-to-drug oncology targets
Proprietary platform: BEYOND / COPPER (generative quantum chemistry + ML)
Founded: 2018
Approx. employees: 27
Known funding: $15.9M (Series A, May 2023) / $15.9M total reported
Company Overview
Problem Domain
Oncology; hard-to-drug protein targets (examples referenced: Myc, KRas G12D, DDR1/2).
Founded
2018
Industry
Biotechnology
Tech Stack
Funding Track Record
15900000
Dealroom lists a May 2023 Series A of $15.9M with participation from Draper Associates, Hatteras Venture Partners, SOSV, Morpheus Ventures and others.
Crunchbase lists a Series A funding round with an announced date of 2024-12-19.
Investor Signal
“Alexandria Venture Investments, Draper Associates, Hatteras Venture Partners, IndieBio, Morpheus Ventures, SOSV, Sigma Group”
Founders
What we do
Join the Team
Startup jobs. A lot of them.
Your next opportunity is in here somewhere. Sign up to explore 70,000+ startups and their open roles. No spam. No gamification. Just jobs.
70,000+
Startups
81,000+
Open Roles
4,600+
New This Week